Bellicum Pharmaceuticals to Present at Three Healthcare Investor Conferences in September
Date/Time: Wednesday, September 6 at 3:00 p.m. EDT
Location: Boston, MA
Event: Ladenburg Thalmann 2017 Healthcare Conference
Date/Time: Tuesday, September 26 at 12:00 p.m. EDT
A live webcast of the fireside chat at
Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. Bellicum is using its proprietary Chemical Induction of Dimerization (CID) technology platform to engineer and control components of the immune system. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), and CAR T and TCR cell therapies. More information can be found at www.bellicum.com.
Bellicum Pharmaceuticals, Inc. Alan Musso, CFO 832-384-1116 email@example.com Media: BMC Communications Brad Miles646-513-3125 firstname.lastname@example.org Source: Bellicum Pharmaceuticals